Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698611 | 0.82 | CHRM4 (0.43) | CHRM4CYP1A2CNR2LRRK2SYK | |
| SCHEMBL20354242 | 0.81 | ACACB (0.40) | CHRM4ACACBCNR2IDH1 | |
| SCHEMBL20354252 | 0.80 | ACACB (0.39) | ACACBIDH1 | |
| SCHEMBL31727812 | 0.79 | CNR2 (0.34) | CHRM4CYP1A2GRIA1CNR2LRRK2 | |
| SCHEMBL17478633 | 0.77 | OPRK1 (0.50) | — | |
| SCHEMBL20354191 | 0.77 | ACACB (0.40) | ACACB | |
| SCHEMBL30867832 | 0.77 | CHRM4 (0.40) | CHRM4CYP1A2GRIA1CNR2LRRK2 | |
| SCHEMBL31195824 | 0.76 | KDM4E (0.51) | LRRK2SYK | |
| SCHEMBL1707909 | 0.76 | KDM4E (0.51) | LRRK2SYK | |
| SCHEMBL17316555 | 0.74 | HTT (0.41) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814393-B2 | Substituted guanidine compounds | UBE CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11814393-B2 | Substituted guanidine compounds | UBE CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11814393-B2 | Substituted guanidine compounds | UBE CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| US-20220315599-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | UBE CORP (JP) | 2022-10-06 | — | — | US | disclosed |
| US-11396514-B2 | Substituted guanidine compounds | UBE CORPORATION | 2022-07-26 | — | — | US | disclosed |
| CN-110114350-B | Substituted guanidine compounds | 宇部兴产株式会社 | 2022-03-04 | — | — | CN | disclosed |
| EP-3564230-B1 | SUBSTITUTED GUANIDINE COMPOUND | UBE INDUSTRIES (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20190337962-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | UBE INDUSTRIES, LTD. (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564230-A1 | SUBSTITUTED GUANIDINE COMPOUND | UBE Industries, Ltd. (JP) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018124179-A1 | SUBSTITUTED GUANIDINE COMPOUND | 宇部興産株式会社 | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315599-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | GMPS, PDE3B, GUCY1A2 | CHRM4 741/4885CYP1A2 226/4885ACACB 3375/4885 |
| US-11814393-B2 | Substituted guanidine compounds | GMPS, PDE3B, GUCY1A2 | CHRM4 741/4885CYP1A2 226/4885ACACB 3375/4885 |
| US-11396514-B2 | Substituted guanidine compounds | GMPS, PDE3B, GUCY1A2 | CHRM4 741/4885CYP1A2 226/4885ACACB 3375/4885 |
| US-20190337962-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | GMPS, PDE3B, GUCY1A2 | CHRM4 741/4885CYP1A2 226/4885ACACB 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.